Paul Tudor Jones's DNLI Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 40,965 shares of Denali Therapeutics Inc. (DNLI) worth $1.05 M, representing 0.00% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in DNLI, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 72,597 shares. Largest reduction occurred in Q3 2024, reducing 58,523 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Denali Therapeutics (DNLI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Denali Therapeutics (DNLI) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +40,965 | New Buy | 40,965 | $25.72 |
| Q1 2026 | -53,683 | Sold Out | 0 | $0.00 |
| Q4 2025 | -2,685 | Reduce 4.76% | 53,683 | $16.51 |
| Q3 2025 | +920 | Add 1.66% | 56,368 | $14.52 |
| Q2 2025 | -17,149 | Reduce 23.62% | 55,448 | $13.99 |
| Q1 2025 | +72,597 | New Buy | 72,597 | $13.59 |
| Q3 2024 | -58,523 | Sold Out | 0 | $0.00 |
| Q2 2024 | -13,128 | Reduce 18.32% | 58,523 | $23.22 |
| Q1 2024 | +71,651 | New Buy | 71,651 | $20.52 |
| Q4 2023 | -42,020 | Sold Out | 0 | $0.00 |
| Q3 2023 | +42,020 | New Buy | 42,020 | $20.63 |
| Q2 2023 | -55,346 | Sold Out | 0 | $0.00 |
| Q1 2023 | +5,415 | Add 10.84% | 55,346 | $0.02 |
| Q4 2022 | +49,931 | New Buy | 49,931 | $0.03 |
| Q3 2022 | -16,464 | Sold Out | 0 | $0.00 |
| Q2 2022 | +16,464 | New Buy | 16,464 | $29.46 |
| Q2 2021 | -39,106 | Sold Out | 0 | $0.00 |
| Q1 2021 | +39,106 | New Buy | 39,106 | $57.10 |
| Q3 2020 | -37,926 | Sold Out | 0 | $0.00 |
| Q2 2020 | +37,926 | New Buy | 37,926 | $24.18 |
Paul Tudor Jones's Denali Therapeutics Investment FAQs
Paul Tudor Jones first purchased Denali Therapeutics Inc. (DNLI) in Q2 2020, acquiring 37,926 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Denali Therapeutics Inc. (DNLI) for 20 quarters since Q2 2020.
Paul Tudor Jones's largest addition to Denali Therapeutics Inc. (DNLI) was in Q1 2025, adding 72,597 shares worth $986,956.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 40,965 shares of Denali Therapeutics Inc. (DNLI), valued at approximately $1.05 M.
As of the Q2 2026 filing, Denali Therapeutics Inc. (DNLI) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Denali Therapeutics Inc. (DNLI) was 72,597 shares, as reported at the end of Q1 2025.